Enlivex Therapeutics Ltd.
| NASDAQ: ENLV | Healthcare / Biotechnology / Israel |
| 3.57 | -0.0900 | -2.46% | Vol 28.02K | 1Y Perf -31.46% |
| Mar 24th, 2023 15:08 DELAYED |
| BID | 3.53 | ASK | 3.57 | ||
| Open | 3.75 | Previous Close | 3.66 | ||
| Pre-Market | - | After-Market | - | ||
| - - | - -% |
| Target Price | 15.00 | Analyst Rating | Strong Buy 1.00 | |
| Potential % | 320.17 | Finscreener Ranking | — - | |
| Insiders Trans % 3/6/12 mo. | -/-/- | Value Ranking | — - | |
| Insiders Value % 3/6/12 mo. | -/-/- | Growth Ranking | — - | |
| Insiders Shares Cnt. % 3/6/12 mo. | -/-/- | Income Ranking | — - | |
| Price Range Ratio 52W % | 2.87 | Earnings Rating | — | |
| Market Cap | 48.06M | Earnings Date | 5th May 2023 | |
| Alpha | 0.00 | Standard Deviation | 0.28 | |
| Beta | 1.12 |
Today's Price Range 3.533.78 | 52W Range 3.428.64 | 5 Year PE Ratio Range -4.10-1.10 |
Summary:
Sell
| Technical Indicators: | Neutral |
| Moving Averages: | Strong Sell |
| Performance | |||
|---|---|---|---|
| 1 Week | 0.28% | ||
| 1 Month | -7.03% | ||
| 3 Months | -8.23% | ||
| 6 Months | -13.14% | ||
| 1 Year | -31.46% | ||
| 3 Years | -18.49% | ||
| 5 Years | - | ||
| 10 Years | - |
| Mngmt Effectiveness | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
ROE (5Y Avg) | -33.66 | |||
ROE last 12 Months | -41.49 | |||
ROA (5Y Avg) | -7.73 | |||
ROA last 12 Months | -36.78 | |||
ROC (5Y Avg) | -66.38 | |||
ROC last 12 Months | -35.35 | |||
Return on invested Capital Q | -8.06 | |||
Return on invested Capital Y | -5.43 | |||
Assets Turnover | 0.00 | |||
Receivables Turnover | 0.00 |
| Valuation | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| -2.70 | ||||
| 1.24 | ||||
| - | ||||
| - | ||||
| -3.20 | ||||
| -1.40 | ||||
| 1.24 | ||||
| 3.44 | ||||
| 44.96M | ||||
| Forward PE | - | |||
| PEG | - |
| Financial Strength | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| 8.80 | ||||
| 13.10 | ||||
| 0.07 | ||||
| 0.08 | ||||
| -62.40 | ||||
| Leverage Ratio | 1.10 |
| Profitability | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| - | ||||
| - | ||||
| - | ||||
| - | ||||
| - |
| Revenue | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| 0.00 | ||||
| 0.00 | ||||
| - | ||||
| - |
| Dividends | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| - | ||||
| - | ||||
| - | ||||
| - | ||||
| Payout ratio | - |
| Earnings History | Estimate | Reported | Surprise % |
|---|---|---|---|
| Q03 2022 | -0.29 | -0.31 | -6.90 |
| Q02 2022 | -0.45 | -0.54 | -20.00 |
| Q01 2022 | -0.41 | -0.45 | -9.76 |
| Q04 2021 | - | -0.26 | - |
| Q03 2021 | -0.21 | -0.19 | 9.52 |
| Q02 2021 | -0.26 | -0.17 | 34.62 |
| Q01 2021 | -0.21 | -0.19 | 9.52 |
| Q04 2020 | - | -0.43 | - |
| Earnings Per End | Estimate | Revision % | Trend |
|---|---|---|---|
| - | - | - | - |
| - | - | - | - |
| - | - | - | - |
| - | - | - | - |
| Next Report Date | 5th May 2023 |
| Estimated EPS Next Report | -0.38 |
| Estimates Count | 1 |
| EPS Growth Next 5 Years % | - |
| Volume Overview | |
|---|---|
| Volume | 28.02K |
| Shares Outstanding | 13.46K |
| Shares Float | 17.22M |
| Trades Count | 141 |
| Dollar Volume | 101.91K |
| Avg. Volume | 19.21K |
| Avg. Weekly Volume | 12.97K |
| Avg. Monthly Volume | 16.96K |
| Avg. Quarterly Volume | 27.70K |
Enlivex Therapeutics Ltd. (NASDAQ: ENLV) stock closed at 3.57 per share at the end of the most recent trading day (a -2.46% change compared to the prior day closing price) with a volume of 28.02K shares and market capitalization of 48.06M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 36 people. Enlivex Therapeutics Ltd. CEO is Oren Hershkovitz.
The one-year performance of Enlivex Therapeutics Ltd. stock is -31.46%, while year-to-date (YTD) performance is -9.33%. ENLV stock has a five-year performance of %. Its 52-week range is between 3.42 and 8.64, which gives ENLV stock a 52-week price range ratio of 2.87%
Enlivex Therapeutics Ltd. currently has a PE ratio of -2.70, a price-to-book (PB) ratio of 1.24, a price-to-sale (PS) ratio of -, a price to cashflow ratio of -, a PEG ratio of 2.32, a ROA of -36.78%, a ROC of -35.35% and a ROE of -41.49%. The company’s profit margin is -%, its EBITDA margin is -%, and its revenue ttm is $0.00 , which makes it $0.00 revenue per share.
Of the last four earnings reports from Enlivex Therapeutics Ltd., there were 0 positive earnings surprise and 3 negative earnings surprise. The company has EPS estimate of $-0.38 for the next earnings report. Enlivex Therapeutics Ltd.’s next earnings report date is 05th May 2023.
The consensus rating of Wall Street analysts for Enlivex Therapeutics Ltd. is Strong Buy (1), with a target price of $15, which is +320.17% compared to the current price. The earnings rating for Enlivex Therapeutics Ltd. stock is (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).
Enlivex Therapeutics Ltd. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.
Enlivex Therapeutics Ltd. has a Sell technical analysis rating based on Technical Indicators (ADX : 18.23, ATR14 : 0.15, CCI20 : -53.29, Chaikin Money Flow : -0.16, MACD : -0.13, Money Flow Index : 27.90, ROC : -6.79, RSI : 34.53, STOCH (14,3) : 26.32, STOCH RSI : 0.56, UO : 42.06, Williams %R : -73.68), Simple Moving Averages and Exponential Moving Averages.
Aggregated Insider Trades of Enlivex Therapeutics Ltd. in the last 12-months were:
Enlivex Therapeutics Ltd.
Enlivex Therapeutics Ltd is an Israel-based development-stage biopharmaceutical company. It is focused on developing and commercializing allogeneic drug pipeline for rebalancing immune hyper-responses. The company's Allocetra is an immunotherapy that is being developed to rebalance a life-threatening unbalanced immune system, using the immune system's own natural regulation mechanisms.
CEO: Oren Hershkovitz
Telephone: +972 26208072
Address: 14 Einstein Street, Nes Ziona 7403618, , IL
Number of employees: 36
